Synopsis: Anondita Medicare Limited has secured a Rs. 7.18 crore government order from CMSS under the NACO program for supply of condoms. The order strengthens the company’s position in preventive healthcare products and improves revenue visibility in the healthcare consumables segment.
Healthcare products stock gained attention after securing a fresh government order for supply of condoms under the National AIDS Control Organisation (NACO) program. The latest development is expected to strengthen the company’s order book and improve revenue visibility in the healthcare consumables segment.
Anondita Medicare Limited has a total market capitalization of Rs. 1,918.99 crore, according to data on the NSE SME platform. Anondita Medicare shares were trading at Rs. 1061 apiece on the National Stock Exchange, up by 1.76 percent; the stock has surged around 6.85 percent over the last five sessions, while it has gone down about 10.83 percent in the 30 days, reflecting mixed overall performance. The stock’s 52-week high was Rs. 1,227 and 52-week low was Rs. 261.75.
Anondita Medicare Limited has announced that it has received a purchase order from Central Medical Services Society (CMSS), Ministry of Health and Family Welfare, Government of India, for supply of condoms under the FS-NACO program.
The order carries a total value of approx Rs. 7.18 crore and relates to supply of condoms under government healthcare and preventive health initiatives. According to the company, the order will be executed in two tranches, with 50 percent delivery to be completed within 90 days from the purchase order date and the remaining 50 percent delivery within 91 to 180 days.
The contract includes standard tender-related conditions including performance security deposit requirements, supply quality checks and payment terms linked to product testing and delivery milestones. Payments are expected within 60–75 days depending on product quality testing requirements. The latest order is strategically important for Anondita Medicare as it strengthens the company’s presence in India’s healthcare consumables and preventive healthcare segment. Government healthcare supply contracts generally improve revenue visibility and support stable order inflows for medical product manufacturers.
A significant portion of Anondita Medicare’s business is linked to institutional and government healthcare procurement programs, particularly through agencies such as CMSS and NACO. Regular government orders provide stable demand visibility, large-volume execution opportunities and support manufacturing capacity utilization for the company. Such contracts also enhance credibility and strengthen the company’s positioning in India’s preventive healthcare and public health supply ecosystem. However, dependence on government orders also creates concentration risk for the business.
If government agencies reduce procurement volumes, delay tender allocations or shift orders to competing manufacturers, the company’s revenue growth and operational utilization could come under pressure. Delays in tender approvals, policy changes or pricing pressures in government contracts may also impact margins and cash flows. To reduce this dependency risk, expansion in private sector sales, exports, branded healthcare products and diversification across healthcare categories will remain important for the company’s long-term growth stability.
India’s healthcare and preventive medical products sector continues witnessing rising demand driven by public healthcare initiatives, increasing awareness regarding preventive healthcare and government-supported health programs. Companies involved in manufacturing healthcare consumables and contraceptive products are expected to benefit from rising institutional demand and healthcare spending.
Anondita Medicare manufactures male and female condoms under its flagship “COBRA” brand along with related healthcare products. The company has integrated manufacturing, printing and packaging facilities and conducts 100 percent electronic testing for product quality assurance. The company has also expanded into female condom manufacturing and has claimed patent-related advancements in production technology. Earlier, the company was also involved in COVID-era healthcare trading products including gloves and face masks.
Overall, the Rs. 7.18 crore government order strengthens Anondita Medicare’s order pipeline and supports future operational growth. Going forward, government healthcare demand, manufacturing scale-up, execution efficiency and expansion across preventive healthcare products will remain key factors influencing the company’s future performance.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post Anondita Medicare Shares Jump 2% After Bagging ₹7.18 Cr Government Order Under NACO Program appeared first on Trade Brains.